Brief: Dawnrays Pharmaceutical Enters Into MAH Assignment Agreement With Nanjing Haina
24/12/2019 14:58
Dec 24 (Reuters) - Dawnrays Pharmaceutical (Holdings) Ltd
2348.HK :
* ENTERED INTO MAH ASSIGNMENT AGREEMENT WITH NANJING HAINA
* NANJING HAINA IS TO ASSIGN MAH IN RESPECT OF FEBUXOSTAT
TABLETS
AND API TO SUZHOU DAWNRAYS
* DEAL FOR RMB240 MILLION
Source text for Eikon: urn:newsml:reuters.com:*:nHKSRRJk6
Further company coverage: 2348.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dawnrays Pharmaceutical (Holdings)
See all newsBrief: Dawnrays Pharmaceutical Says Suzhou Dawnrays Commits To Invest Up To RMB100 Mln In Partnership
Brief: Dawnrays Pharmaceutical (Holdings) Final Dividend Of Hk$0.048 Per Share
Brief: Dawnrays Pharmaceutical Reports HY Net Income Attributable Of RMB104.6 MLN
Brief: Dawnrays Pharmaceutical (Holdings) Posts FY Profit Attributable Of Rmb564.9 Million
Brief: Dawnrays Pharmaceutical (Holdings) Appoints Yu Liwei To Act As CEO